CD34 and acute myeloid leukemia: We hypothesized that eliminating the dying, non-leukemic and differentiated AML blasts (CD34-) may provide a unique window into the biology arising from known clinical prognostic factors, while potentially improving the prognostic performance of expression biomarkers.